Slide 1: Zymeworks Delaware Redomicile Webcast
Zymeworks Delaware Redomicile Webcast Neil Klompas Chief Operating Officer
Slide 2: Important Information and Where to Find It
This communication is not intended to and does not constitute an offer to sell, buy or exchange or the solicitation of an offer to sell, buy or exchange any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, purchase, or exchange of securities or
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of Canadian securities laws, or collectively, forward looking statements. Forward-lo
Slide 4: Strategically Aligned and Better Positioned to Build Value
Strategically Aligned and Better Positioned to Build Value Reduction in workforce KEY STRATEGIC PRIORITIES FOR 2022 & 2023 STATUS / TARGET Improve financial position Financial Partnerships & Collaborations Preclinical and Platforms Advance two new product candidate to IND stage Clinical Monetize exi
Slide 5: Select Potential Benefits to Delaware Redomicile
Select Potential Benefits to Delaware Redomicile Enhances alignment with current and future shareholders to Delaware corporate law Allows for potential expansion due to elimination of investment size limitations for Canadian domiciled securities Greater familiarity and comparability with other Delaw
Slide 6: Tax-Efficient Redomicile Process Overview
Tax-Efficient Redomicile Process Overview Redomicile described in detail in preliminary proxy statement / prospectus on form S-4 to be filed with the United States Securities and Exchange Commission (“SEC”) by Zymeworks Delaware Inc. Document describes a share exchange process through which common s
Slide 7: Strategically Aligned and Better Positioned to Build Value
Strategically Aligned and Better Positioned to Build Value Reduction in workforce KEY STRATEGIC PRIORITIES FOR 2022 & 2023 STATUS / TARGET Improve financial position Financial Partnerships & Collaborations Preclinical and Platforms Advance two new product candidate to IND stage Clinical Monetize exi
Slide 8: Appendix
Appendix
Slide 9: Corporate Structure Prior to the Reorganization
Corporate Structure Prior to the Reorganization Zymeworks Inc. Zymeworks Management Inc. UK Branch Zymeworks Biopharmaceuticals Inc. Zymeworks Delaware Inc. Zymeworks Pharmaceuticals Limited Zymeworks Callco ULC Zymeworks Exchangeco Ltd. United Kingdom Canada Ireland United States Canada
Slide 10: Corporate Structure Following the Reorganization
Corporate Structure Following the Reorganization Zymeworks Delaware Inc. (to be renamed Zymeworks Inc.) Zymeworks Pharmaceuticals Limited Ireland Zymeworks Biopharmaceuticals Inc. United States Zymeworks Callco ULC Zymeworks Exchangeco Ltd. Zymeworks Inc. (to be renamed Zymeworks BC Inc.) Zymeworks